SUPERNUS PHARMACEUTICALS, INC. Share-based Payment Arrangement, Expense, Tax Benefit
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Share-based Payment Arrangement, Expense, Tax Benefit of $300.00 thousand for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-10.
Discontinued › Expense Statement › Income Tax
us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense · last filed 2019-05-10
- SUPERNUS PHARMACEUTICALS, INC. share-based payment arrangement, expense, tax benefit for the quarter ending 2019-03-31 was $300.00K, a 85.00% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. share-based payment arrangement, expense, tax benefit for the quarter ending 2018-09-30 was $700.00K.
- SUPERNUS PHARMACEUTICALS, INC. share-based payment arrangement, expense, tax benefit for the quarter ending 2018-06-30 was $4.40M.
- SUPERNUS PHARMACEUTICALS, INC. share-based payment arrangement, expense, tax benefit for the quarter ending 2018-03-31 was $2.00M.
| Period end | Share-based Payment Arrangement, Expense, Tax Benefit 3 month | Share-based Payment Arrangement, Expense, Tax Benefit 6 month | Share-based Payment Arrangement, Expense, Tax Benefit 9 month |
|---|---|---|---|
| 2019-03-31 | $300.00K 10-Q · filed 2019-05-10 | ||
| 2018-09-30 | $700.00K 10-Q · filed 2018-11-09 | $5.10M derived: sum of 2 quarters · filed 2018-11-09 | $7.00M 10-Q · filed 2018-11-09 |
| 2018-06-30 | $4.40M 10-Q · filed 2018-08-09 | $6.40M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $2.00M 10-Q · filed 2019-05-10 | ||
| 2017-09-30 | $2.90M 10-Q · filed 2017-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |